Skip to main content
. 2019 Feb 14;11(2):222. doi: 10.3390/cancers11020222

Figure 10.

Figure 10

Percentage tumor growth inhibition (% TGI) in Group III (treated by NT 3–12 peptide-loaded NPs 10 mg kg−1) relative to Group I (control group).